Clearmind Medicine Inc (CMND)
Clearmind Medicine Inc. is a clinical-stage pharmaceutical company listed on NASDAQ under the ticker CMND. The company focuses on developing psychedelic-based medicines aimed at a range of unmet medical needs, including alcohol use disorder, binge drinking, eating disorders, obesity, metabolic syndrome, anxiety, post-traumatic stress disorder, depression, and treatment-resistant depression. Its pipeline includes MEAI, which is being studied for alcohol use disorder, obesity, and metabolic conditions, as well as an alcohol substitute consumer product. The company is also advancing CM-CMND-001, which is in Phase I/IIa testing for alcohol use disorder. Clearmind has entered into collaborations with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CMND
|
$2.77
|
61.3% Upside
|
Bargain
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 10, 2026
|
-0.3x
|
0.2x
|
—
|
2.778 M
|
-10.951 M
|
3.0%
|
99.9%
|
1.0
|
—
|
78.7%
|
